- Trials with a EudraCT protocol (815)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
815 result(s) found for: prostate cancer.
Displaying page 36 of 41.
EudraCT Number: 2013-005325-23 | Sponsor Protocol Number: SGB_HF_MEN | Start Date*: 2014-06-20 |
Sponsor Name:Rijnstate Hospital | ||
Full Title: Short-term Efficacy of Stellate Ganglion Block in Men to reduce Hot Flushes related to Androgen Deprivation Therapy | ||
Medical condition: Hot flushes due to androgen deprivation therapy | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002529-27 | Sponsor Protocol Number: D5339C00001 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) | |||||||||||||
Medical condition: Advanced Cancer Whose Tumours Contain Molecular Alterations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000345-39 | Sponsor Protocol Number: B9991032 | Start Date*: 2019-02-19 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors | ||||||||||||||||||
Medical condition: locally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defect | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) BE (Completed) DK (Completed) ES (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004486-86 | Sponsor Protocol Number: SRA737-01 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003424-76 | Sponsor Protocol Number: CTX-SPL9111-001 | Start Date*: 2018-01-30 | |||||||||||
Sponsor Name:Starpharma Pty Ltd | |||||||||||||
Full Title: A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced ... | |||||||||||||
Medical condition: Patients with advanced solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007241-12 | Sponsor Protocol Number: PH-L19SIPI131-07/07 | Start Date*: 2008-10-06 | |||||||||||
Sponsor Name:Philogen S.p.A. | |||||||||||||
Full Title: A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER | |||||||||||||
Medical condition: Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024237-23 | Sponsor Protocol Number: CDI-CS-001 | Start Date*: 2011-05-06 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | |||||||||||||
Full Title: An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors | |||||||||||||
Medical condition: Advanced or recurrent solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003822-25 | Sponsor Protocol Number: EORTC 08051 | Start Date*: 2006-06-19 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
Medical condition: Stage IB-II Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006214-26 | Sponsor Protocol Number: GU07-123 | Start Date*: 2009-09-07 |
Sponsor Name:Hoosier Oncology Group | ||
Full Title: Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladder | ||
Medical condition: operable bladder cancer (T2 to T4a) lymph node negative disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015122-11 | Sponsor Protocol Number: GBG54 | Start Date*: 2012-08-27 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in m... | |||||||||||||
Medical condition: Breast Cancer in Male Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000707-28 | Sponsor Protocol Number: ICR-CTSU/2008/10016 | Start Date*: 2009-03-23 | |||||||||||
Sponsor Name:The Institute of Cancer Research [...] | |||||||||||||
Full Title: A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis | |||||||||||||
Medical condition: Locally advanced and metastatic carcinoma of the penis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004211-31 | Sponsor Protocol Number: CCR3894 | Start Date*: 2014-08-20 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | ||
Medical condition: Adverse effects of radiotherapy for pelvic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004036-36 | Sponsor Protocol Number: 178-MA-1008 | Start Date*: 2016-07-18 | |||||||||||
Sponsor Name:Astellas Pharma Global development, Inc | |||||||||||||
Full Title: A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi- Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While ... | |||||||||||||
Medical condition: Over active bladder (OAB) in men with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) PL (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003584-53 | Sponsor Protocol Number: Debio1347-201 | Start Date*: 2019-02-05 |
Sponsor Name:Debiopharm International SA | ||
Full Title: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 | ||
Medical condition: Three cohorts will be included consisting of subjects with biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and all other solid tumor histologies not included in Cohorts 1-2 such as NS... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) GR (Completed) AT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DK (Completed) NO (Completed) BG (Completed) FI (Completed) ES (Temporarily Halted) HR (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003135-30 | Sponsor Protocol Number: URO-901-3005 | Start Date*: 2019-12-12 | |||||||||||
Sponsor Name:Urovant Sciences GmbH | |||||||||||||
Full Title: A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacolog... | |||||||||||||
Medical condition: Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: LT (Completed) ES (Ongoing) HU (Completed) PT (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002190-49 | Sponsor Protocol Number: REO 008 | Start Date*: 2006-11-08 | |||||||||||
Sponsor Name:Oncolytics Biotech Inc | |||||||||||||
Full Title: A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With ... | |||||||||||||
Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no standard curative therapy exists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001735-10 | Sponsor Protocol Number: 21816 | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in parti... | |||||||||||||
Medical condition: Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000570-21 | Sponsor Protocol Number: MADS | Start Date*: 2008-02-05 | |||||||||||
Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO | |||||||||||||
Full Title: Randomized phase II study of adjuvant chemotherapy with cisplatin + vinorelbine vs gemcitabine + vinorelbine in stage IB-IIIA radically resected non-small cell lung cancer (NSCLC) patients | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005108-89 | Sponsor Protocol Number: VHIO17002 | Start Date*: 2019-01-25 | |||||||||||
Sponsor Name:Vall d’Hebron Institute of Oncology (VHIO) | |||||||||||||
Full Title: Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors. | |||||||||||||
Medical condition: Subjects with advanced solid tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005965-20 | Sponsor Protocol Number: ML20938 | Start Date*: 2007-03-07 |
Sponsor Name:Roche AB | ||
Full Title: EFFECTS OF THREE TREATMENT STRATEGIES ON ANEMIA AND QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS OR LYMPHOPROLIFERATIVE MALIGNANCIES: A RANDOMIZED 3-ARM STUDY ON ACTIVE (A) OR CONVENTIONAL (C) TRA... | ||
Medical condition: Anemia in patients with cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
